Heparin harmonization on the horizon?
This article was originally published in The Gold Sheet
Executive Summary
Both the United States Pharmacopeia and the European Pharmacopoeia Commission have announced that their respective pharmacopoeias have adopted revised monographs for heparin calcium and heparin sodium that are more closely aligned with each other. The Japanese Pharmacopoeia is currently reviewing a draft revision for heparin sodium. These announcements follow the recent serious problems with heparin, including 81 deaths, and the emergency measures to react to the safety issues involved
You may also be interested in...
U.S. Pharmacopeia Ramps Up Drug Quality, Safety Cooperation Across Asia With Four New Agreements With China, ASEAN States
BEIJING - In moves that could ultimately help elevate safety and quality standards for drugs produced across Asia, including those exported to North America, the United States Pharmacopeial Convention has signed a series of agreements with China and the Association of Southeast Asian Nations on closer scientific exchanges and joint testing of pharmaceuticals
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.